AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Insider Transactions Reported | ImageneBio(IMA)saw insider trading activity on 7/30/2025
ByAinvest
Thursday, Jul 31, 2025 6:00 am ET1min read
ImageneBio(IMA) saw insider trading activity on 7/30/2025, there were 3 insider trades during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 7/30/2025 | -- | ORBIMED ADVISORS LLC | Buy | 83611 | 2.49 | 208.19k |
| 7/30/2025 | -- | Bonita David P、Stampacchia Otello | Buy | 351167 | 29.90 | 10499.89k |
| 7/29/2025 | Chief Financial Officer | Marango Jotin | Sell | 4630 | 17.16 | 79.45k |
| 6/24/2022 | -- | Bonita David P、ORBIMED ADVISORS LLC | Buy | 0 | 3.55 | 0.0k |
| 6/24/2022 | -- | Bonita David P、ORBIMED ADVISORS LLC | Buy | 0 | 5.37 | 0.0k |
| 6/24/2022 | -- | Bonita David P、ORBIMED ADVISORS LLC | Buy | 0 | 4.37 | 0.0k |
| 6/24/2022 | -- | Bonita David P、ORBIMED ADVISORS LLC | Buy | 0 | 3.71 | 0.0k |
| 1/20/2022 | Chief Business Officer | Tessier Maude | Buy | 38915 | 2.94 | 114.41k |
| 1/20/2022 | Chief Business Officer | Tessier Maude | Buy | 24606 | 4.15 | 102.11k |
| 1/20/2022 | Chief Business Officer | Tessier Maude | Buy | 8265 | 4.51 | 37.28k |
[Company Profile]
ImageneBio, Inc. was incorporated as a Delaware corporation on March 2, 2016 and is headquartered in Boston, Massachusetts. The company is a targeted oncology company focused on developing novel cancer therapies targeting the critical signaling pathways that drive cancer formation and spread. The company's projects focus on key cancer-driven pathways that are well validated in the scientific literature but lack approved or effective treatments, and thus have the potential to address highly unmet medical needs. By leveraging a deep understanding of discovery chemistry, translational science and patient-centered drug development, the company has established an in-depth pipeline of wholly owned and partnered projects focused on gene-defined or biomarker-driven cancers, able to target specific patient groups that the company believes are most likely to respond to the treatment of product candidates. Since commencing operations in 2016, the company has discovered or developed five oncology programs, including four product candidates in IND research or clinical development.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet